SCSusan Lerner Cohn

Susan Lerner Cohn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susan Lerner Cohn has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reply to: “Hypoxia‐Induced Lineage Plasticity in Neuroblastoma: Advancing Signature Interpretation and Clinical Translation”

    by Gepoliano S. Chaves, Mohansrinivas Chennakesavalu, Kelley Moore, Hannah Adams, Cara Chittenden, Emma Wilkinson, Omar Vayani, Maria E. Kaufman, Alexandre Chlenski, Chuan He, et al.

  • Open Access

    A Bayesian‐Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in Neuroblastoma

    by Lin Xu, Arhanti Sadanand, Evan W. Neczypor, Yen‐Ting Liu, Erin Butler, Kelley Moore, Flannery Bowman, Yamin Mazumder, Arlene Naranjo, Alexandre Chlenski, et al.

    Identifying targetable oncogenic drivers remains a challenge in neuroblastoma, the most common extracranial solid malignancy in children. We applied a Bayesian algorithm for integrative analysis of expression and copy‐number, iExCN, to nominate oncogenic drivers in neuroblastoma. The iExCN algorithm found 47 oncogenes from a dataset of 195 neuroblastoma biopsy specimens. The nominated oncogenes included some previously implicated in neuroblastoma, including ALK , MDM2 , MYCN , and XPO1 , but most have not been linked to this disease. A CRISPR/Cas9‐based screen testing those candidates revealed neuroblastoma cell line‐specific and shared vulnerabilities in three well‐characterized models, and dependencies were confirmed by complementary RNA knockdown. Analysis of more than 30 additional neuroblastoma cell lines using DepMap confirmed statistically significant dependency scores in the iExCN genes. Finally, analysis of two cohorts of children with neuroblastoma revealed a trend toward worse survival in cases in which more iExCN genes showed copy number gains. Our findings uncover multiple, potentially targetable oncogenic drivers that appear to influence neuroblastoma biology, demonstrating a generalizable capacity for iExCN to unmask disease genes and therapeutic targets in cancer.

  • Open Access

    Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma

    by Gepoliano S. Chaves, Mohansrinivas Chennakesavalu, Kelley Moore, Hannah Adams, Cara Chittenden, Emma Wilkinson, Omar Vayani, Maria E. Kaufman, Alexandre Chlenski, Chuan He, et al.

    Adrenergic (ADRN) neuroblastoma cells have a paradoxical increase in TET1 expression and 5‐hydroxymethylcytosine (5‐hmC) deposition in hypoxia. However, the effect of hypoxia on the mesenchymal (MES) lineage remains less well understood. To identify lineage specific hypoxia responses, we evaluated 5‐hmC and RNA expression in a panel of ADRN and MES cells cultured in normoxic or hypoxic conditions. In hypoxia, MES cells had only a modestly elevated expression of hypoxia signaling and no phenotypic changes. In contrast, ADRN cells showed increased 5‐hmC deposition and decreased mitochondrial function in hypoxia. In hypoxia, only ADRN cells had increased expression of MES signature genes ( p < 0.05) and related pathways including TNF‐α signaling. Publicly available RNA‐Seq data of diagnostic tumors was accessed (GSE62564 and GSE73517). Each tumor was assigned a hypoxia score using a published hypoxia signature. A MES/hypoxia signature comprising 94 MES signature genes that had increased expression in ADRN cells exposed to hypoxia was also generated. This MES/hypoxia signature was significantly correlated with a T cell infiltration signature ( r = 0.66, p = 2.3 × 10 −12 ). Kaplan–Meier analysis and the log rank test assessed overall survival (OS) differences between groups. High‐risk patients with hypoxic tumors that had high MES/hypoxia scores had significantly improved 3‐year OS compared to those with low MES/hypoxia scores (71% vs. 40%; p = 0.0054). Superior survival was also observed in high‐risk patients with hypoxic tumors that had high MES/hypoxia scores in the validation cohort (GSE73517; n = 28; 3‐year OS 78% vs. 26%, p = 0.0012). Our results suggest that hypoxia changes expression of genes in ADRN cells towards MES cells.


  • Open Access

    Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group

    by Florette K. Hazard, Angus M.S. Toland, Serena Y. Tan, Bill Chiu, Naohiko Ikegaki, Arlene Naranjo, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, et al.

    Statistical Framework of INPC-Risk Grouping System

  • Open Access

    Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group

    by Florette K. Hazard, Angus M.S. Toland, Serena Y. Tan, Bill Chiu, Naohiko Ikegaki, Arlene Naranjo, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, et al.

    Purpose:Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC).Experimental Design:The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors.Results:This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC.Conclusions:The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.

  • Open Access

    Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group

    by Florette K. Hazard, Angus M.S. Toland, Serena Y. Tan, Bill Chiu, Naohiko Ikegaki, Arlene Naranjo, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, et al.

    International Neuroblastoma Pathology Classification.

  • Open Access

    Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group

    by Florette K. Hazard, Angus M.S. Toland, Serena Y. Tan, Bill Chiu, Naohiko Ikegaki, Arlene Naranjo, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, et al.

    Children’s Oncology Group Revised Neuroblastoma Risk Classification.

  • Adaptive Clinical Neuroblastoma Risk Groups—Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project

    by Wendy B. London, Gabriela Villanueva, Derek Shyr, Jaques van Heerden, Soad Fuentes-Alabi, Raya Saab, Derek Harrison, Ruzanna Papyan, Hoa Thi Kim Nguyen, Dolly Noun, et al.

    PURPOSE: Risk/treatment stratification for children with neuroblastoma (NB) relies on clinical, histologic, and genomic factors. However, most children with cancer live in low- and middle-income countries (LMIC), where access to advanced methods for stratification is limited. To address this unmet need, we developed a novel risk/treatment classification, the Adaptive Clinical Neuroblastoma Risk Groups (ACNRG) using clinical prognostic biomarkers. PATIENTS AND METHODS: A survival tree regression analysis of the International Neuroblastoma Risk Group (INRG) Data Commons (N = 14,501, diagnosed 1990-2014) was performed using univariate Cox regression models (age, International Neuroblastoma Staging System, serum lactate dehydrogenase [LDH], and serum ferritin) of event-free survival (EFS), separately for test and validation sets. Within each terminal node of the survival tree, the proportion of patients by initial treatment assignment and outcome achieved on that treatment were used to subjectively assign risk/treatment intensity (low-, intermediate-, and high-risk). For additional validation, the ACNRG was descriptively compared with INRG classification. Guidelines were developed for determining INRGs Staging System (INRGSS) in LMIC, using the minimum essential versus optimal imaging/biopsy procedures. RESULTS: Twelve statistically, clinically significant unique pretreatment risk groups of INRGSS/age/LDH/ferritin were identified (5-year EFS): low—L1/any/any/any (92% ± 0.5%); intermediate—L2/<18 months/<1,400/any (88% ± 1%), MS/any/<1,400/any (86% ± 1.5%), M/<12 months/<1,400/any (76% ± 2.3%); intermediate/high—L2/<18 months/≥1,400/any (73% ± 4.7%), L2/≥18 months/<1,400/<30 (68% ± 3.4%), L2/≥18 months/<1,400/≥30 (59% ± 3.7%), MS/any/≥1,400/any (52% ± 6.3%); high—L2/≥18 months/≥1,400/any (46% ± 4.7%), M/12-18 months/<1,400/any (64% ± 4.1%), M/<18 months/≥1,400/any (60% ± 1.6%), M/≥18 months/any/any (28% ± 0.8%). The concordance and discordance rates of ACNRG versus INRG were 86.6% and 13.4%, respectively (n = 8,152 nonmissing-data intersection). CONCLUSION: The ACNRG classification, using easily obtained clinical markers, is highly prognostic. The ACNRG could transform risk and treatment stratification, improve accuracy of treatment intensity decisions, and potentially improve outcome, for the large number of children with NB in LMIC. Prospective validation of the ACNRG classification is planned in a pilot trial.


  • Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group

    by Florette K. Hazard, Angus M.S. Toland, Serena Y. Tan, Bill Chiu, Naohiko Ikegaki, Arlene Naranjo, Susan L. Cohn, Wendy B. London, Julie M. Gastier-Foster, Nilsa C. Ramirez, et al.

    Purpose: Historically, neuroblastoma risk stratification has been performed with clinical stage as the starting point and successively adding other prognostic factors thereafter. This study takes an alternative approach to define risk groups of patients with neuroblastoma by starting with the International Neuroblastoma Pathology Classification (INPC). Experimental Design: The cohort of patients with neuroblastoma previously used for developing the Children’s Oncology Group–Revised Neuroblastoma Risk Classification (RNRC) system was reanalyzed by survival tree regression analysis, starting with the INPC distinguishing favorable-histology and unfavorable-histology categories. The resultant two branches were further divided first by the International Neuroblastoma Risk Group Staging System and successively by other prognostic factors. Results: This new stratification system, the INPC-Risk Grouping (INPC-RG), is simpler than the RNRC system, eliminating unnecessary decision trees, and distinguishes four risk groups (groups I–IV). Using only INPC (unfavorable histology) and International Neuroblastoma Risk Group Staging System (stage M), INPC-RG defines patients with highly aggressive group IV tumors, whose 5-year event-free survival was worse than that of the RNRC high-risk group. Additionally, it identifies group III patients whose 5-year event-free survival spanned 50% to 80%, which was not identified by the RNRC. Conclusions: The benefits of using this new INPC-RG system are fourfold: (1) it allows for the rapid identification of group IV patients, (2) it lays the foundation for further refinement of group III, (3) it can stratify patients when the amount of tumor tissue is limited, and (4) it allows patients in resource-limited areas to be appropriately stratified, potentially improving the worldwide treatment of patients with neuroblastoma.


  • Open Access

    International neuroblastoma risk group consortium: a model of networking for rare cancers

    by Susan L Cohn, Wendy B London, Gudrun Schleiermacher, Lucas Moreno, Inge M Ambros, Peter F Ambros, Rochelle Bagatell, Maja Beck Popovic, Klaus Hermann Beiske, Frank Berthold, et al.

    It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.